Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Clinical trial NCT03220477 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03220477
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-04
- Primary completion
- 2027-07-01
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.